Education
About Us
Working with TipRanks
Follow Us
Cresco Labs OTC (CRLBF)
:CRLBF
Earnings Data
Report Date
May 14, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.03Last Year’s EPS
-0.01Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 12, 2025
|% Change Since: 5.41%
|Next Earnings Date:May 14, 2025
Earnings Call Sentiment|Neutral
Cresco Labs demonstrated strong cash flow and operational improvements, with strategic expansions in key markets. However, these achievements were offset by revenue declines and margin pressures due to price compression and supply constraints. The company is positioning itself for long-term growth, but faces near-term challenges.Company Guidance
In the Cresco Labs Fourth Quarter 2024 Earnings Conference Call, the company provided comprehensive financial guidance and strategic initiatives for future growth. They reported a total revenue of $724 million for the full year 2024, reflecting a 6% year-over-year decline, but they maintained their adjusted gross profit dollars flat and managed to reduce adjusted SG&A expenses by $29 million. This resulted in a 15% growth in adjusted EBITDA to $200 million and a 126% improvement in operating cash flow, reaching $132 million. For the fourth quarter, Cresco Labs achieved $176 million in revenue and $42 million in adjusted EBITDA, representing 24% of revenue, despite facing price compression and supply constraints in key markets. Looking forward, Cresco Labs plans to maintain its profitability focus in 2025 by driving productivity in core markets and strategically expanding its footprint with new store openings in Pennsylvania, Florida, and Ohio, as well as entering Kentucky's medical cannabis market with a significant cultivation license. The company is also prioritizing independent retailers over multi-state operators (MSOs) to manage accounts receivable risk and ensure long-term sustainability.Improved Cash Flow and Profitability
Cresco Labs generated $132 million in operating cash flow in 2024, a $74 million improvement from last year, and a $200 million adjusted EBITDA, a $26 million improvement.
Successful Market Expansion
Cresco Labs strengthened its position in Pennsylvania by adding three new dispensaries and plans to expand in Pennsylvania, Florida, and Ohio in 2025. The company also entered the Kentucky market, securing a cultivation license with 25,000 square feet of canopy.
Retail Performance
Cresco Labs' dispensaries were 30% more productive than the market average, maintaining retail revenue year-over-year despite price compression.
Debt Reduction and Strong Financial Position
Cresco Labs retired $40 million of its 2026 note and plans to refinance, showing strong demand from lenders and a commitment to reducing debt.
---
CRLBF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CRLBF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 12, 2025 | $0.74 | $0.74 | 0.00% |
| Nov 08, 2024 | $1.28 | $1.24 | -3.13% |
| Aug 08, 2024 | $1.45 | $1.62 | +11.72% |
| May 15, 2024 | $2.02 | $2.09 | +3.47% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Cresco Labs OTC (CRLBF) report earnings?
Cresco Labs OTC (CRLBF) is schdueled to report earning on May 14, 2025, TBA Not Confirmed.
What is Cresco Labs OTC (CRLBF) earnings time?
Cresco Labs OTC (CRLBF) earnings time is at May 14, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRLBF EPS forecast?
CRLBF EPS forecast for the fiscal quarter 2025 (Q1) is -0.03.
---